Romania Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Oct. 1, 2006 - 77 Pages

Table of Contents

Chapter 1 - Executive Summary

Romania Pharmaceuticals & Healthcare Industry SWOT

Romania Economic SWOT

Romania Business Environment SWOT

Chapter 2 - Business Environment Rankings

Central & Eastern Europe Region

Table: Central & Eastern Europe Pharmaceuticals Business

Environment Ranking

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Issues

Pricing and Reimbursement

Healthcare Sector Developments

Chapter 5 - Industry Forecast Scenario

Overall Market Forecast

Table: Drug Market Indicators

Key Growth Factors - Industry

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: Real GDP By Expenditure

OTC Market Forecast

Table: OTC Market Indicators

Prescription Market Forecast

Table: Prescription Drug Market Indicators

Generics Market Forecast

Table: Generics and Branded Market Indicators

Export/Import Forecasts

Table: Sectoral Trade Indicators

Other Healthcare Data Forecasts

Table: Socio-Demographic Indicators

Key Risks to BMI’s Forecast Scenario

Chapter 6 - Competitive Landscape

Manufacturing

Table: Sindan Q206 Product Launches

Distribution Sector

Wholesale Sector

Retail Sector

Romania Pharmaceuticals & Healthcare Report Q3 2006

Table: Pharmacies & Pharmacy Market Ratios

Chapter 7 - Company Monitor

Antibiotice Iasi

GlaxoSmithKline (Europharm)

Terapia-Ranbaxy

Zentiva (incorporating Sicomed)

Chapter 8 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 9 - Appendix: Regional Demographic Data

Wages (ave. labour force per annum), US$ PPP

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 10 - Country Snapshot: Romania Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Abstract

Romania's pharmaceuticals market is characterised by high growth and increasing levels of foreign direct investment ahead of planned EU accession. The value of Romania's pharmaceutical market in 2005 was US$1.4bn at retail prices and strong growth is predicted, making investment in the country more attractive. By 2010, the value of the pharmaceuticals industry is forecast to reach nearly US$2bn.

The 18% increase in market size in 2005 was primarily attributed to improved consumer access to medicines. Penetration by foreign firms is also increasing. The market share of imported drugs rose from 45% to 75% in the nine years to 2004; however, these products accounted for only a fifth of the sales by volume, which suggests that local low-cost drugs are popular and widespread. Growth of the generics sector is forecast to be 15-20% per annum, while the total market will grow by 10-15% per annum in the mid-term.

BMI's adjusted Business Environment Rankings for Central & Eastern Europe place Romania fourth out of the 14 markets in the survey, which is a significant improvement compared to last quarter's 11th position. The primary reason for the rise is the country's reassessed market growth potential which is higher than most of its neighbours. Romania, like other CEE nations, is also demonstrating improved political and economic risk as the region embraces EU membership.

For the remainder of 2006, the upturn is forecast to continue, with year-on-year growth expected to be between the current rate of 14.5% and last year's 18% towards the end of 2006. These growth figures are a clear indication of the buoyancy of Romania's market. Recent high-profile acquisitions by Czech firm Zentiva and India's Ranbaxy, coupled with the exit of many smaller firms over the last couple of years, have transformed the domestic landscape, and will further boost the market.

Following EU accession in January 2007, the prices of pharmaceuticals in Romania are set to rise, which will negatively affect consumers in the short term but will ultimately benefit them. The move is in order to prevent parallel importers from plundering the country's wholesale medicine warehouses, leading to shortages of drugs in hospitals and pharmacies. The Ministry of Health is currently drafting the appropriate policy with regard to raising prices and a document is expected in the coming months.

Key Benefits of Report

Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.

Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments

Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.